• Enrico Costa, Enrico Sterzi, Federico Tedeschi, Rebecca Casari, Paola Marini, and Fabio Lugoboni.
• Department of Pharmacy, Azienda Ospedaliera Universitaria Integrata Verona,, P. le L.A. Scuro, 10, 37134, Verona, Italy. enrico.costa@aovr.veneto.it.
• Intern Emerg Med. 2021 Apr 1; 16 (3): 785-788.

AbstractThe slowness of dripping and the presence of alcohol have been offered/suggested as possible causes for the increased risk of developing dependence to the oral formulation of lormetazepam rather than to other anxiolytic and hypnotic drugs. We hence assessed the time of dripping of the most used benzodiazepines and z-drugs oral solution products under experimental conditions and the different employed excipients through a comparative analysis of the Summaries of Product Characteristics. A wide range of the median overall dispensing time was found across the eight products included in the analysis. Among the products containing LMZ, Minias® ranked in the fourth position, while LMZ Mylan Generics® and Noctamid® in the sixth and third, respectively. Our data suggest that the pace of dripping and the presence of alcohol cannot be considered themselves the cause that triggered the abuse of lormetazepam. More precisely, the quantity of alcohol per bottle has been found negligible at therapeutic doses; however, when these are exceeded, they may have clinical implications for patients. Further studies are needed to assess them. Meanwhile, the public-health problem remains and some improvements should be carried out at different levels, to guarantee the appropriate prescription and use of lormetazepam oral solution.

18 keywords...

hide…